Upsher-Smith Laboratories, LLC, a United States-based pharmaceutical company, announced on Monday that it has launched its Pitavastatin Tablets in 1mg, 2mg, and 4mg strengths.
The product is an AB-rated, generic equivalent to the brand product, LIVALO (pitavastatin) tablets.
Sawai USA, Inc, a company of Sawai Group Holdings Co., Ltd. (Sawai), has the ANDA for Pitavastatin tablets and it represents Sawai's first Paragraph IV product to be introduced in the United States. The company is distributing the product in the United States.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream